Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin and breast cancer risk

This article was originally published in The Tan Sheet

Executive Summary

The use of aspirin and other non-steroidal anti-inflammatory drugs and acetaminophen is not associated with a reduced risk of breast cancer among premenopausal women in a study published online in the Internal Archives of Medicine Jan. 26. Led by Harvard researcher A. Heather Eliassen, the trial followed 112,292 women ages 25 to 42 who completed a lifestyle questionnaire for the Nurses' Health Study II in 1989; subjects were followed through 2003. Overall, 1,345 cases of invasive premenopausal breast cancer were documented. Results did not vary by frequency, dose or duration of use. The findings run counter to a meta-analysis published in the Oct. 7 Journal of National Cancer Institute, which concluded NSAIDs, including aspirin and ibuprofen, are associated with a reduced risk of breast cancer (1"The Tan Sheet" Oct. 13, 2008, In Brief)
Advertisement

Related Content

NSAIDs use may cut breast cancer risk

Topics

Advertisement
UsernamePublicRestriction

Register

PS102549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel